Seminars in Nuclear Medicine
Volume 40, Issue 1 , Pages 52-61 , January 2010

Miscellaneous Indications in Bone Scintigraphy: Metabolic Bone Diseases and Malignant Bone Tumors

  • Gary J.R. Cook, MBBS, MSc, MD, FRCR, FRCP

      Affiliations

    • Department of Nuclear Medicine and PET, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
    • Corresponding Author InformationAddress reprint requests to Gary J.R. Cook, MBBS, MSc, MD, FRCR, FRCP, Department of Nuclear Medicine and PET, The Royal Marsden NHS Foundation Trust, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • Gopinath Gnanasegaran, MD

      Affiliations

    • Department of Nuclear Medicine, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom
    • ,
  • Sue Chua, MBBS, BSc, FRCR

      Affiliations

    • Department of Nuclear Medicine and PET, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

References 

  1. Hughes S, Khan R, Davies R, et al. The uptake by the canine tibia of the bone-scanning agent 99mTc-MDP before and after an osteotomy. J Bone Joint Surg Br. 1978;60-B:579–582
  2. Blake GM, Holohan SJP, Cook GJR, et al. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49
  3. Fogelman I, Bessent RG, Turner JG, et al. The use of whole-body retention of Tc99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270–275
  4. Fogelman I, Bessent RG, Cohen HN, et al. Skeletal uptake of diphosphonate (Method for prediction of postmenopausal osteoporosis). Lancet. 1980;2:667–670
  5. Front D, Israel O, Jerushalmi J, et al. Quantitative bone scintigraphy using SPECT. J Nucl Med. 1989;30:240–245
  6. Israel O, Lubushitzky R, Frenkel A, et al. Bone turnover in cortical and trabecular bone in normal women and in women with osteoporosis. J Nucl Med. 1994;35:1155–1158
  7. Cook GJR, Lodge MA, Blake GM, et al. Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride PET. J Bone Miner Res. 2000;15:763–769
  8. Frost ML, Blake GM, Park-Holohan SJ, et al. Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. J Nucl Med. 2008;49:700–707
  9. Frost ML, Cook GJ, Blake GM, et al. The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover. J Clin Densitom. 2007;10:46–54
  10. Frost ML, Fogelman I, Blake GM, et al. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res. 2004;19:1797–1804
  11. Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970–1976
  12. Frost ML, Cook GJ, Blake GM, et al. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Miner Res. 2003;18:2215–2222
  13. Spitz J, Lauer I, Tittel K, et al. Scintimetric evaluation of remodeling after bone fractures in man. J Nucl Med. 1993;34:1403–1409
  14. Eastell R, Cedel SL, Wahner HW, et al. Classification of vertebral fractures. J Bone Miner Res. 1991;6:207–215
  15. Ryan PJ, Fogelman I. Osteoporotic vertebral fractures: Diagnosis with radiography and bone scintigraphy. Radiology. 1994;190:669–672
  16. Cook GJR, Hannaford E, Lee M, et al. The value of bone scintigraphy in the evaluation of osteoporotic patients with back pain. Scand J Rheumatol. 2002;31:245–248
  17. Ryan PJ, Evans PA, Gibson T, et al. Osteoporosis and chronic back pain: A study with single photon emission computed bone scintigraphy. J Bone Miner Res. 1992;7:1455–1459
  18. Fogelman I, Carr D. A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget's disease. Eur J Nucl Med. 1980;5:417–421
  19. Rotés-Sala D, Monfort J, Solano A, et al. The clover and heart signs in vertebral scintigraphic images are highly specific of Paget's disease of bone. Bone. 2004;34:605–608
  20. Estrada WN, Kim CK. Paget's disease in a patient with breast cancer. J Nucl Med. 1993;34:1214–1216
  21. Ryan PJ, Gibson T, Fogelman I. Bone scintigraphy following pamidronate therapy for Paget's disease of bone. J Nucl Med. 1992;33:1589–1593
  22. Patel S, Pearson D, Hosking DJ. Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone. Arthritis Rheum. 1995;38:1506–1512
  23. Ryan WG, Fordham EW, Ali A. Treated Paget's disease of bone mimicking metastatic cancer. Clin Nucl Med. 1995;20:69
  24. Smith ML, Fogelman I, Ralston S, et al. Correlation of skeletal uptake of 99mTc-diphosphonate and alkaline phosphatase before and after oral diphosphonate therapy in Paget's disease. Metab Bone Dis Relat Res. 1984;5:167–170
  25. Pons F, Alvarez L, Peris P, et al. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity. Nucl Med Commun. 1999;20:525–528
  26. Hadjipavlou A, Lisbona R, Garbuz D, et al. Whole body retention of Tc99m phosphate in Paget's disease of bone. Clin Nucl Med. 1991;16:435–438
  27. Vellenga CJ, Pauwels EK, Bijvoet OL, et al. Quantitative bone scintigraphy in Paget's disease treated with APD. Br J Radiol. 1985;58:1165–1172
  28. Vellenga CJ, Pauwels EK, Bijvoet OL. Comparison between visual assessment and quantitative measurement of radioactivity on the bone scintigram in Paget's disease of bone. Eur J Nucl Med. 1984;9:533–537
  29. Fogelman I, Bessent RG, Gordon D. A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease. Eur J Nucl Med. 1981;6:93–97
  30. Griffith K, Pearson D, Parker C, et al. The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease. Nucl Med Commun. 2001;22:1069–1075
  31. Cook GJ, Blake GM, Marsden PK, et al. Quantification of skeletal kinetic indices in Paget's disease using dynamic18F-fluoride positron emission tomography. J Bone Miner Res. 2002;17:854–859
  32. Installé J, Nzeusseu A, Bol A, et al. (18)F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. J Nucl Med. 2005;46:1650–1658
  33. Cook GJR, Maisey MN, Fogelman I. Paget's disease of bone: Appearances with 18-FDG PET. J Nucl Med. 1997;38:1495–1497
  34. Fogelman I, Carr D. A comparison of bone scanning and radiology in the evaluation of patients with metabolic bone disease. Clin Radiol. 1980;31:321–326
  35. Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: Correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949–955
  36. Fogelman I, McKillop JH, Bessent RG, et al. The role of bone scanning in osteomalacia. J Nucl Med. 1978;19:245–248
  37. Fogelman I, McKillop JH, Greig WR, et al. Pseudofractures of the ribs detected by bone scanning. J Nucl Med. 1977;18:1236–1237
  38. McLean RG, Murray IP. Scintigraphic patterns in certain primary bone tumours. Clin Radiol. 1984;35:379–383
  39. Simon MA, Kirchner PT. Scintigraphic evaluation of primary bone tumours. J Bone Joint Surg. 1980;62:758–764
  40. McKillop JH, Etcubanas E, Goris ML. The indications for and the limitations of bone scintigraphy in osteogenic sarcoma. Cancer. 1981;48:1133–1138
  41. Goldmann AB, Becker MH, Braunstein P, et al. Bone scanning—Osteogenic sarcoma (Correlation with surgical pathology). Radiology. 1975;124:83–90
  42. Papanicolou N, Kozakewich H, Treves S, et al. Comparison of the extent of osteosarcoma between surgical pathology and skeletal scintigraphy. J Nucl Med. 1982;23:7
  43. Chew FS, Hudson TM. Radionuclide bone scanning of osteosarcoma: Falsely extended uptake patterns. AJR Am J Roentgenol. 1982;139:49–54
  44. Ghaed N, Thrall JH, Pinsky SM, et al. Detection of extraosseous metastases from osteosarcoma with 99mTc-polyphosphate bone scanning. Radiology. 1974;112:3373–3375
  45. Ozcan Z, Burak Z, Kumanlioglu K, et al. Assessment of chemotherapy-induced changes in bone sarcomas: Clinical experience with 99mTc-MDP three-phase dynamic bone scintigraphy. Nucl Med Commun. 1999;20:41–48
  46. Knop J, Delling G, Heise U, et al. Scintigraphic evaluation of tumor regression during preoperative chemotherapy of osteosarcoma (Correlation of 99mTc-methylene diphosphonate parametric imagingwith surgical histopathology). Skeletal Radiol. 1990;9:165–172
  47. Sommer HJ, Knop J, Heise U, et al. Histomorphometric changes of osteosarcoma after chemotherapy (Correlation with 99mTc methylene diphosphonate functional imaging). Cancer. 1987;59:252–258
  48. Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing's sarcoma to preoperative chemotherapy: Assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990;175:791–796
  49. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: Standardized uptake value in 52 lesions. Radiology. 2001;219:774–777
  50. Dimitrakopoulou-Strauss A, Strauss LG, et al. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med. 2002;43:510–518
  51. Tian R, Su M, Tian Y, et al. Dual-time point PET/CT with F-18FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol. 2009;38:451–458
  52. Strobel K, Exner UE, Stumpe KD, et al. The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2008;35:2000–2008
  53. Völker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: Results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435–5441
  54. Kleis M, Daldrup-Link H, Matthay K, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging. 2009;36:23–36
  55. Kneisl JS, Patt JC, Johnson JC, et al. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas?. Clin Orthop Relat Res. 2006;450:101–104
  56. Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: Comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305–1311
  57. Györke T, Zajic T, Lange A, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun. 2006;27:17–24
  58. Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT. Ann Oncol. 2001;12:479–486
  59. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637–1643
  60. Nair N, Ali A, Green AA, et al. Response of osteosarcoma to chemotherapy (Evaluation with 18F-FDG-PET scans). Clin Positron Imaging. 2000;3:79–83
  61. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828–8834
  62. Hawkins DS, Rajendran JG, Conrad EU, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer. 2002;94:3277–3284
  63. Franzius C, Sciuk J, Brinkschmidt C, et al. Evaluation of chemotherapy response in primary bone tumors with F-18FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874–881
  64. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med. 1996;37:1438–1444
  65. Franzius C, Bielack S, Flege S, et al. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002;43:1012–1017
  66. Costelloe CM, Macapinlac HA, Madewell JE, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50:340–347

PII: S0001-2998(09)00068-3

doi: 10.1053/j.semnuclmed.2009.08.002

Seminars in Nuclear Medicine
Volume 40, Issue 1 , Pages 52-61 , January 2010

Article Tools

* Image Usage & Resolution